340 related articles for article (PubMed ID: 28118826)
1. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
2. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
[TBL] [Abstract][Full Text] [Related]
3. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
4. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
5. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
6. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients.
De Backer J; Vos W; Van Holsbeke C; Vinchurkar S; Claes R; Parizel PM; De Backer W
Int J Chron Obstruct Pulmon Dis; 2013; 8():569-79. PubMed ID: 24293993
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
8. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
[TBL] [Abstract][Full Text] [Related]
9. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen Y; Cai W; Lei S; Zhang Z
COPD; 2014 Jun; 11(3):351-8. PubMed ID: 24378052
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine administration confers lung protection in different phases of lung ischaemia-reperfusion injury.
Forgiarini LF; Forgiarini LA; da Rosa DP; Silva MB; Mariano R; Paludo Ade O; Andrade CF
Interact Cardiovasc Thorac Surg; 2014 Dec; 19(6):894-9. PubMed ID: 25156898
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review.
Sadowska AM; Manuel-Y-Keenoy B; De Backer WA
Pulm Pharmacol Ther; 2007; 20(1):9-22. PubMed ID: 16458553
[TBL] [Abstract][Full Text] [Related]
12. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
13. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.
Calzetta L; Matera MG; Rogliani P; Cazzola M
Expert Rev Respir Med; 2018 Aug; 12(8):693-708. PubMed ID: 29972340
[TBL] [Abstract][Full Text] [Related]
14. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
[TBL] [Abstract][Full Text] [Related]
15. Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation.
Rocksén D; Lilliehöök B; Larsson R; Johansson T; Bucht A
Clin Exp Immunol; 2000 Nov; 122(2):249-56. PubMed ID: 11091282
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents.
Mitsopoulos P; Omri A; Alipour M; Vermeulen N; Smith MG; Suntres ZE
Int J Pharm; 2008 Nov; 363(1-2):106-11. PubMed ID: 18694812
[TBL] [Abstract][Full Text] [Related]
17. Oral N-acetylcysteine attenuates pulmonary emphysema and alveolar septal cell apoptosis in smoking-induced COPD in rats.
Cai S; Chen P; Zhang C; Chen JB; Wu J
Respirology; 2009 Apr; 14(3):354-9. PubMed ID: 19341424
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine abrogates acute lung injury induced by endotoxin.
Kao SJ; Wang D; Lin HI; Chen HI
Clin Exp Pharmacol Physiol; 2006; 33(1-2):33-40. PubMed ID: 16445696
[TBL] [Abstract][Full Text] [Related]
19. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
20. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]